JP2025102784A5 - - Google Patents

Info

Publication number
JP2025102784A5
JP2025102784A5 JP2025034660A JP2025034660A JP2025102784A5 JP 2025102784 A5 JP2025102784 A5 JP 2025102784A5 JP 2025034660 A JP2025034660 A JP 2025034660A JP 2025034660 A JP2025034660 A JP 2025034660A JP 2025102784 A5 JP2025102784 A5 JP 2025102784A5
Authority
JP
Japan
Prior art keywords
fusion protein
cas9 polypeptide
terminal fragment
cas9
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025034660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025102784A (ja
Filing date
Publication date
Priority claimed from JP2021544294A external-priority patent/JP7646552B2/ja
Application filed filed Critical
Publication of JP2025102784A publication Critical patent/JP2025102784A/ja
Publication of JP2025102784A5 publication Critical patent/JP2025102784A5/ja
Pending legal-status Critical Current

Links

JP2025034660A 2019-01-31 2025-03-05 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ Pending JP2025102784A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962799702P 2019-01-31 2019-01-31
US62/799,702 2019-01-31
JP2021544294A JP7646552B2 (ja) 2019-01-31 2020-01-31 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
PCT/US2020/016285 WO2020160514A1 (en) 2019-01-31 2020-01-31 Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021544294A Division JP7646552B2 (ja) 2019-01-31 2020-01-31 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ

Publications (2)

Publication Number Publication Date
JP2025102784A JP2025102784A (ja) 2025-07-08
JP2025102784A5 true JP2025102784A5 (cg-RX-API-DMAC7.html) 2025-10-31

Family

ID=71842366

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544294A Active JP7646552B2 (ja) 2019-01-31 2020-01-31 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
JP2025034660A Pending JP2025102784A (ja) 2019-01-31 2025-03-05 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021544294A Active JP7646552B2 (ja) 2019-01-31 2020-01-31 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ

Country Status (8)

Country Link
US (1) US20220098572A1 (cg-RX-API-DMAC7.html)
EP (1) EP3918078A4 (cg-RX-API-DMAC7.html)
JP (2) JP7646552B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210121113A (cg-RX-API-DMAC7.html)
CN (1) CN114040977B (cg-RX-API-DMAC7.html)
AU (1) AU2020215730A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127493A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020160514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA3100019A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
AU2021230546A1 (en) 2020-03-04 2022-10-13 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20230159913A1 (en) 2020-04-28 2023-05-25 The Broad Institute, Inc. Targeted base editing of the ush2a gene
KR20230061474A (ko) * 2020-09-04 2023-05-08 고쿠리츠다이가쿠호진 고베다이가쿠 소형화 시티딘 데아미나아제를 포함하는 이중쇄 dna의 개변용 복합체
CN116601293A (zh) * 2020-12-07 2023-08-15 中国科学院动物研究所 工程化的Cas效应蛋白及其使用方法
CN112195164B (zh) * 2020-12-07 2021-04-23 中国科学院动物研究所 工程化的Cas效应蛋白及其使用方法
CA3214494A1 (en) * 2021-03-26 2022-09-29 Beam Therapeutics Inc. Adenosine deaminase variants and uses thereof
CA3224970A1 (en) * 2021-07-06 2023-01-12 Holly A. REES Compositions and methods for efficient genome editing
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20250361530A1 (en) * 2022-05-14 2025-11-27 The Regents Of The University Of California Genome editing systems for multiplexing point mutation introduction in living cells
CN119591727B (zh) * 2023-12-06 2025-09-30 北京齐禾生科生物科技有限公司 优化的qbe碱基编辑系统及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166982A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
WO2015089486A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
CN114438169B (zh) * 2014-12-20 2024-11-08 阿克生物公司 使用CRISPR/Cas系统蛋白靶向消减、富集、和分割核酸的组合物及方法
EP3250689B1 (en) * 2015-01-28 2020-11-04 The Regents of The University of California Methods and compositions for labeling a single-stranded target nucleic acid
EP3303634B1 (en) * 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
WO2016205613A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzyme mutations reducing off-target effects
WO2017048969A1 (en) * 2015-09-17 2017-03-23 The Regents Of The University Of California Variant cas9 polypeptides comprising internal insertions
SG11201803173VA (en) * 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
JP7231935B2 (ja) * 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
SG10201913505WA (en) * 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
US10745677B2 (en) * 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
KR20240116572A (ko) * 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
AU2018290843B2 (en) * 2017-06-26 2025-04-24 Massachusetts Institute Of Technology CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing

Similar Documents

Publication Publication Date Title
JP2025102784A5 (cg-RX-API-DMAC7.html)
US20220213507A1 (en) Aav delivery of nucleobase editors
US20250115884A1 (en) TAL-Tet1 Fusion Proteins and Methods of Use Thereof
US12157760B2 (en) Base editors and uses thereof
US11840694B2 (en) Truncated CRISPR-Cas proteins for DNA targeting
AU2018272067B2 (en) Base editors with improved precision and specificity
EP3178935B1 (en) Genome editing using campylobacter jejuni crispr/cas system-derived rgen
CN110612353A (zh) 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
JP2017018125A5 (cg-RX-API-DMAC7.html)
CN108291218A (zh) 核酸酶非依赖性靶向基因编辑平台及其用途
JP2016537008A5 (cg-RX-API-DMAC7.html)
CN110520163A (zh) 独立于dna双链断裂的靶向基因编辑平台及其用途
EP2776560A2 (en) Endonuclease for genome editing
JPWO2020168132A5 (cg-RX-API-DMAC7.html)
JPWO2021050571A5 (cg-RX-API-DMAC7.html)
JPWO2020160514A5 (cg-RX-API-DMAC7.html)
Li et al. Site-directed RNA editing by harnessing ADARs: advances and challenges
JPWO2020181102A5 (cg-RX-API-DMAC7.html)
CN103764820A (zh) 序列特异性工程改造的核糖核酸酶h和用于确定dna-rna杂交物结合蛋白序列偏好的方法
CN118147120A (zh) 胞苷脱氨酶及碱基编辑器
JPWO2020219908A5 (cg-RX-API-DMAC7.html)
US20200263204A1 (en) Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion
KR20250148471A (ko) 핵산 결합 단백질 및 SsdA를 포함하는 융합단백질 및 이의 용도
KR20200125191A (ko) 표적 특이적 crispr 변이체
KR20250140037A (ko) 박테리아 톡신 변이체 및 이의 용도